Harnessing the power of KISIMA® immunisation technology to discover and develop therapeutic vaccines
A novel approach to therapeutic vaccines
AMAL aims to tackle the obstacles for effective anti-cancer therapy by stimulating a patient’s immune system in a unique way.
First-in-class immunisation technology
KISIMA®, our unique proprietary protein-based immunisation platform is self-adjuvanting and delivers several antigens in one single vaccine.
Transforming the prospects of cancer patients
We focus on the development of viable effective cancer therapies. Our most advanced asset is ATP128, a therapeutic vaccine for the treatment of metastatic colorectal cancers.
November 1-5, 2023 / San Diego / USA
Matteo Rossi, Head of in vivo Research, presenting
mRNA Cancer Vaccines Summit 2023
October 10-12, 2023 / Boston / USA
Marie-Laure Santiago-Raber, Senior Director Non-Clinical Development, attending
September 20-23, 2023 / Milano / Italy
Elodie Belnoue, Senior Director Translational Research, presenting